Aethlon Medical Inc
$ 4.03
8.92%
04 Dec - close price
- Market Cap 3,068,100 USD
- Current Price $ 4.03
- High / Low $ 4.08 / 3.57
- Stock P/E 0.02
- Book Value 7.55
- EPS 209.20
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.91 %
- 52 Week High 84.40
- 52 Week Low 3.42
About
Aethlon Medical, Inc. (AEMD) is an innovative medical technology company headquartered in San Diego, California, dedicated to developing cutting-edge products for the diagnosis and treatment of critical and organ-threatening diseases. With a robust proprietary platform, Aethlon focuses on addressing significant unmet medical needs, thereby improving patient outcomes. The company's strong commitment to research and development solidifies its position as a key player in the medical technology sector, actively advancing therapeutic solutions that cater to the evolving healthcare landscape.
Analyst Target Price
$12.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-06-27 | 2025-02-12 | 2024-11-12 | 2024-08-14 | 2024-06-26 | 2024-02-14 | 2023-11-14 | 2023-08-10 | 2023-06-28 | 2023-02-13 |
| Reported EPS | -3.74 | -0.85 | -3.44 | -0.13 | -0.2 | -0.34 | -0.91 | -1.37 | -1.22 | -0.14 | -0.1 | -0.12 |
| Estimated EPS | -1.08 | -0.73 | -1.11 | -0.2033 | -0.19 | -0.31 | -1.25 | -1.23 | -1.4 | -0.13 | -0.13 | -0.08 |
| Surprise | -2.66 | -0.12 | -2.33 | 0.0733 | -0.01 | -0.03 | 0.34 | -0.14 | 0.18 | -0.01 | 0.03 | -0.04 |
| Surprise Percentage | -246.2963% | -16.4384% | -209.9099% | 36.0551% | -5.2632% | -9.6774% | 27.2% | -11.3821% | 12.8571% | -7.6923% | 23.0769% | -50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AEMD
2025-10-16 14:31:55
This article reports a client-side application error when trying to load content from ng.investing.com. It indicates that further information can be found in the browser console. The original topic relates to Aethlon Medical enacting a 1-for-10 reverse stock split.
2025-10-16 13:51:23
Aethlon Medical, Inc. has announced a 1-for-10 reverse stock split, effective October 16, 2025, to manage dilution and comply with Nasdaq listing requirements. The company faces significant financial challenges, including persistent losses, and its stock is currently rated as a Hold with a $1.50 price target. TipRanks' AI Analyst "Spark" rates AEMD as Underperform due to these financial issues and negative technical indicators.
2025-10-16 13:44:36
This article reports a client-side exception occurred while loading content from Investing.com. It indicates that Aethlon Medical is enacting a 1-for-10 reverse stock split effective Thursday, according to the article title. However, the body of the article content is missing due to the error.
2025-10-16 13:34:50
The article reports that Aethlon Medical is implementing a 1-for-10 reverse stock split. This corporate action will become effective on Thursday. No additional details are available in the provided content.
2025-10-16 13:30:00
Aethlon Medical is enacting a 1-for-10 reverse stock split, effective Thursday. However, the article content appears to be incomplete, indicating a client-side exception when loading the page.
2025-10-16 13:29:00
Aethlon Medical, Inc. implemented a 1-for-10 reverse stock split effective Thursday, reducing the number of outstanding shares and adjusting authorized share capital. This action follows a nearly 90% decline in the company's stock value year-to-date, with the stock trading on a split-adjusted basis on Nasdaq starting Monday. The company also recently announced early positive observations from its oncology clinical trial and a public offering to raise approximately $4.5 million.
